In turn, in the study by Stämpfli et al., which included an exploratory analysis of data on the pharmacological safety of oxytocin and its analogue carbetocin in the context of adverse hemodynamic effects, it was shown that the use of carbetocin is associated with an increased number of reports of hypertension, hypotension, and tachycardia compared to oxytocin [16]. This evidence concerns the gene OXT and hypertensive disorder.